胶质瘤
癌症研究
免疫系统
髓样
免疫疗法
川地163
转录组
医学
生物
免疫组织化学
多路复用
融合蛋白
肿瘤进展
肿瘤微环境
髓系细胞
巨噬细胞
免疫荧光
小胶质细胞
干扰素
信号转导
肿瘤坏死因子α
免疫学
抗体
抗原呈递
血管生成
M2巨噬细胞
脑瘤
肿瘤相关巨噬细胞
基因表达谱
细胞因子
融合基因
星形细胞瘤
先天免疫系统
髓源性抑制细胞
作者
Chengjun Zheng,Qiaodong Chen,Zheng Fang,Yutong Feng,Ying Zhang,Zhaoshi Bao
出处
期刊:Neuro-oncology
[Oxford University Press]
日期:2026-11-01
卷期号:28 (Supplement_4): noag189.1302-
标识
DOI:10.1093/neuonc/noag189.1302
摘要
Recurrent IDH-mutant high-grade gliomas remain difficult to treat, with limited effective therapies. PTPRZ1–MET (ZM) fusion is enriched during malignant progression, present in ∼15% of secondary glioblastomas and associated with markedly poorer survival. How ZM fusion remodels the immune microenvironment and whether it creates exploitable vulnerabilities remain unclear. We investigated ZM fusion–associated immune remodeling and evaluated combined MET and LGALS9 targeting. Single-cell RNA sequencing was performed on six recurrent IDH-mutant high-grade gliomas. Myeloid populations were resolved by subclustering and module-based annotation, and ligand–receptor analyses compared intercellular communication by fusion status. A fusion-associated macrophage signature informed prognostic modeling via Cox regression, LASSO, and random forest. MET and LGALS9 expression were validated by immunohistochemistry and multiplex immunofluorescence with spatial line-scan analysis. Therapeutic efficacy was assessed in an immunocompetent orthotopic IDH-mutant/ZM fusion GL261 model treated with anti-LGALS9 antibody (RG9-1), MET inhibitor vebreltinib, or their combination. scRNA-seq identified a ZM fusion–associated microglia-like macrophage program marked by enhanced antigen presentation and myeloid activation, which supported a prognostic risk score stratifying patient outcomes. Cell–cell communication analysis revealed strengthened MET–LGALS9 interactions between tumor and myeloid compartments in fusion-positive tumors. Transcriptomic profiling demonstrated elevated type I interferon responses in fusion-positive tumor cells with altered IFN-I regulatory nodes in microglial populations. Tissue validation confirmed higher MET expression in tumor cells and higher LGALS9 in myeloid/microglial cells with close spatial proximity. In vivo, combined RG9-1 and vebreltinib produced the strongest tumor suppression and longest survival versus monotherapy or control. PTPRZ1–MET fusion defines a recurrent IDH-mutant glioma subset with distinctive immunosuppressive remodeling. A fusion-associated MET–IFN-β–LGALS9 axis links tumor-intrinsic interferon signaling to macrophage-mediated immune regulation, providing mechanistic rationale for combined MET and LGALS9 targeting.
科研通智能强力驱动
Strongly Powered by AbleSci AI